Abstract: Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.

Abstract: A dry particulate mix for use in yeast leavened bakery products, includes: 3-90 wt. % of non-fermentable carbohydrates, including at least 3 wt. % of a non-fermentable sugar alcohol; 0-50 wt. % of fermentable sugars; two or more bakery ingredients selected from the group consisting of: 10-90 wt. % of viable yeast; 10-50 wt. % of baking powder; 5-90 wt. % of emulsifier; 3-50 wt. % of ascorbic acid; and 0.0001-1 wt. % of bakery enzyme; all of these percentages being calculated on the combined amount of these two to five bakery ingredients; and wherein the weight ratio of non-fermentable carbohydrates to fermentable sugars exceeds 1:1. A sweetened dough is obtainable by incorporating therein 3-75% by weight of the final dough of the dry particulate mix.

Abstract: The present invention relates to a method for preparing a monoglyceride hydrate product, which product may be used as an emulsifier in various food and non-food applications. The present invention further relates to the monoglyceride hydrate product obtainable by said method. The invention further relates to a monoglyceride hydrate product, comprising monoglycerides, with saturated fatty acid residues, water and non-hydrogenated monoglycerides and/or diglycerides having unsaturated fatty acid residues.

Abstract: Processes for increasing expression of a MTOR gene or a mTOR protein or decreasing expression of a MSTN gene or a myostatin protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% Type-A polymers by weight. The Type-A polymers include A-Type doubly-linked procyanidin oligomers of the catechins and/or epicatechins. The processes further include increasing expression of a MTOR gene or a mTOR protein or decreasing expression of a MSTN gene or a myostatin protein in the subject by the step of administering.

Abstract: A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the Cinnamonum aromaticum, Cinnamonum verum or Cinnamonum burmannii plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein.

Abstract: Provided are process of regulating expression of one or more genes or proteins involved in circadian rhythm. A subject such as a cell is administered or contacted to an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active agents in the extracts administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.

Abstract: A composition containing cinnamon extract reduces and/or eliminates one or more risk factors associated with Syndrome X. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing and/or eliminating risk factors associated with Syndrome X in a subject through the administration of the cinnamon extract. The cinnamon extract supplement is administered orally, intravenously, or subcutaneously. In one embodiment, a daily dose of 10-1,000 mg of the cinnamon extract supplement is administered to the subject for a period of 6 weeks to 6 months.

Abstract: Extracting lipids from a feedstock includes contacting a feedstock including water, lipids, and solid organic matter with an organic solvent to yield a mixture; separating the mixture to yield a solid and a liquid; and desolventizing the solid to yield a solid product and a fluid product. The organic solvent may include a polar organic solvent, a non-polar organic solvent, or a combination thereof. The lipids in the mixture are in the liquid state. The solid product has a lipids content of 20 wt % or less. In some cases, the number-weighted particle size distribution of the solid organic matter has a mean dimension of 1 mm or less, the lipids content of the feedstock is at least 20 wt %, the water content of the feedstock is 10 wt % or less or 5 wt % or less, or a combination thereof.

Abstract: Novel yeast-raised and other bakery products and methods of making those products are provided. The products are formed from dough having a thermally-stable amyloglucosidase, and a raw starch degrading amyloglucosidase and/or an anti-staling amylase. The level of added sugar included in the dough can be substantially reduced, and even eliminated, while still achieving a sweet product. Additionally, the resulting bakery product is free of, or at least substantially free of, fructose. The final baked product will also have improved texture properties, including superior firmness, resilience, and adhesiveness and can be made with a reduced amount of yeast.

Abstract: The present invention is directed to methods and compositions for making dough-based bakery foods, such as bread having extended mold-free shelf-lives, using new antimicrobial powders comprising an antimicrobial agent dispersed in a carrier. The invention is also directed to methods and compositions for preparing dough-based bakery products, such as bread, having long mold-free shelf-lives, by treating the surface of the dough with the antimicrobial powder. Further, the invention is concerned with bakery products having long, mold-free and anti-staling shelf-lives.

Abstract: Extracting lipids from a feedstock includes contacting a feedstock including water, lipids, and solid organic matter with an organic solvent to yield a mixture; separating the mixture to yield a solid and a liquid; and desolventizing the solid to yield a solid product and a fluid product. The lipids in the mixture are in the liquid state. The solid product has a lipids content of 20 wt % or less. In some cases, the number-weighted particle size distribution of the solid organic matter has a mean dimension of 1 mm or less, the lipids content of the feedstock is at least 20 wt %, the water content of the feedstock is 10 wt % or less, or a combination thereof.

Abstract: A composition containing nelumbo extract reduces and/or eliminates one or more risk factors associated with Metabolic syndrome. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing and/or eliminating risk factors associated with Metabolic syndrome in a subject through the administration of the nelumbo extract. The nelumbo extract supplement is administered orally, intravenously, or subcutaneously. In one embodiment, a daily dose of 10-1,000 mg of the extract supplement is administered to the subject for a period of 6 weeks to 6 months.

Abstract: Interacted starch products made up of resistant starch and hydrocolloid are provided which exhibit at least about 20% resistance to ?-amylase digestion. The products are prepared by mixing together quantities of resistant starch and hydrocolloid in water with mixing and optional heating, followed by drying. Foods containing the interacted starch products are also disclosed.

Abstract: A method of making crystalline benzoyl peroxide particles having a particle size no greater than 25 microns and formed by wet milling in the absence of solvents and wherein the crystalline benzoyl peroxide is not irritating to the skin. A method of making a therapeutic or cosmetic composition comprising a water-based gel containing the crystalline benzoyl peroxide.

Abstract: A method for promoting weight loss and/or lowering blood glucose comprises an active material which may be cinnamon, an extract of cinnamon, or a derivative of a cinnamon extract. The active material may be utilized in combination with further active ingredients.

Abstract: The present invention comprises an edible swirl imparting carrier for flavor or color or flavor and color. The edible carrier comprises a coating effective for imparting a color in a viscous or visco-elastic matrix when moved in the matrix. The present invention also includes a method for imparting a swirl of color in a viscous or visco-elastic medium.

Abstract: A concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel.

Abstract: A method of making crystalline benzoyl peroxide particles having a particle size no greater than 25 microns and formed by wet milling in the absence of solvents and wherein the crystalline benzoyl peroxide is not irritating to the skin. A method of making a therapeutic or cosmetic composition comprising a water-based gel containing the crystalline benzoyl peroxide.

Abstract: Disclosed herein are dry blends used in the process of making cheese analogues with an improved economic profile. Further, the blends disclosed herein may be used to make 100% analogue, vegan, or low-moisture cheeses.

Abstract: The present invention involves a new synthesis route for the formation of lactylates. The method comprises reacting a dilactide with a compound comprising a hydroxy group. This reaction is preferably carried out in the presence of a cation or other source of alkalinity. Preferred compounds comprising a hydroxy group include any fatty acid and fatty acid alcohol (particularly C1-C26 fatty acid chains). Preferred cations include cations of Group I and II metals, with sodium, calcium, and potassium cations being particularly preferred. The inventive reactions proceed much more rapidly than prior art lactylate synthesis reactions, and can be used to form 1-, 2-, 3-, 4-, and 5-lactylates.